A database of FDA approved therapeutic peptides and proteins
| ID | ThPPID | Name | Peptide Sequence | Length | Functional Classification | Disease | Brand | Company | Physical Appearance | Route of Administartion | Category | Target |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1441 | Th1077 | Urofollitropin | Alpha chain:APDVQDCP Full view | 203 | Ib | Hormonal | Fertinex | N.A. | Sterile, lyophilized form contains an acidic, water soluble glycoprotein biologically standardized for FSH gonadotropin activity | Subcutaneous injection. | Fertility Agents | Glutamate carboxypeptidase 2 |
| 1442 | Th1078 | Efalizumab | Light Chain:DIQMTQSP Full view | 229 | IIa | Immunological | RAPTIVA | Genentech, Inc. | Sterile, white to off-white, lyophilized powder in single-use glass vials | Subcutaneous injection. | Immunosuppressive Agents | Iduronic acid |
| 1456 | Th1086 | Interferon Alfa-2B, Recombinant | CDLPQTHSLGSRRTLMLLAQ Full view | 165 | Ib | Immunological | INTRON® A | Merck | Powder or solution | Intramuscular, Subcutaneous, Intralesional, or Intravenous injection | Immunosuppressive Agents | Granulocyte colony-stimulating factor receptor,Neutrophil elastase, Coagulation factor X,Coagulation factor XI,Coagulation factor VII,Coagulation factor VIII,Prothrombin,Prolow-density lipoprotein receptor-related protein 1,Vitamin K-dependent gamma-carboxylase, Platelet-derived growth factor receptor beta,Platelet-derived growth factor receptor alpha,Alpha-2-macroglobulin |
| 1462 | Th1088 | Enfuvirtide | YTSLIHSLIEESQNQQEKNE Full view | 36 | IIa | Infectious | `FUZEON | Trimeris, Roche | White to off-white, sterile, lyophilized powder. | Subcutaneous injection | HIV Fusion Inhibitors | Oxytocin receptor,Oxytocin-neurophysin 1, Envelope glycoprotein |
| 1482 | Th1100 | Pramlintide | KCNTATCATQRLANFLVHSS Full view | 37 | Ia | Hormonal/Metabolic | Symlin | Amylin Pharmaceuticals (now a wholly owned subsidiary of AstraZeneca) | Clear, isotonic, sterile solution | Subcutaneous injection | N.A. | Calcitonin receptor,Receptor activity-modifying protein 1,Receptor activity-modifying protein 2,Receptor activity-modifying protein 3 |
| 1495 | Th1102 | Abatacept | MHVAQPAVVLASSRGIASFV Full view | 357 | IIa | Immunological | ORENCIA | Bristol-Myers Squibb | Lyophilized powder, supplied as a sterile, white, preservative-free, lyophilized powder for intravenous administration | Intravenous infusion and Subcutaneous injection | Antirheumatic Agents and Immunosuppressive Agents | T-lymphocyte activation antigen CD80,T-lymphocyte activation antigen CD86 |
| 1502 | Th1105 | Insulin Aspart | A chain: GIVEQCCTSIC Full view | 51 | Ia | Hormonal/Metabolic | NovoLog | Novo Nordisk | Sterile, aqueous, clear, and colorless solution | Subcutaneous injection, Intravenous injection | Hypoglycemic Agents and Antidiabetic Agents | Insulin receptor |
| 1503 | Th1105 | Insulin Aspart | A chain: GIVEQCCTSIC Full view | 51 | Ia | Hormonal/Metabolic | NovoLog Mix 50/50 | Novo Nordisk | Uniform, white, sterile suspension that contains insulin aspart | Subcutaneous injection | Hypoglycemic Agents and Antidiabetic Agents | Insulin receptor |
| 1504 | Th1105 | Insulin Aspart | A chain: GIVEQCCTSIC Full view | 51 | Ia | Hormonal/Metabolic | NovoLog Mix 70/30 | Novo Nordisk | Uniform, white, sterile suspension that contains insulin aspart 100 Units/mL. | Subcutaneous injection | Hypoglycemic Agents and Antidiabetic Agents | Insulin receptor |
| 1511 | Th1106 | Insulin Detemir | A chain: GIVEQCCTSIC Full view | 51 | Ia | Hormonal/Metabolic | LEVEMIR | Novo Nordisk | Clear, colorless, aqueous, neutral sterile solution | Subcutaneous injection | Antidiabetic Agents | Insulin receptor |
| 1531 | Th1110 | Thymalfasin | SDAAVDTSSEITTKDLKEKK Full view | 28 | Ib | Infectious/Immunological | Zadaxin | SciClone Pharmaceuticals (SCLN) | N.A. | Subcutaneous injection | N.A. | N.A. |
| 1533 | Th1112 | Natural Alpha Interferon Or Multiferon | Inteferon alpha-1: | 997 | IIa | Cancer/Infectious | Intron/ Roferon-A | N.A. | N.A. | Subcutaneous injection, Intravenous injection, Intramuscular injection | N.A. | N.A. |
| 1534 | Th1113 | Glatiramer Acetate | EAYKAAEKAYAAKEAAKEAA Full view | 52 | IIa | Neurological Disorder | Copaxone | Teva Pharmaceutical Industries | Clear, colorless to slightly yellow, sterile, nonpyrogenic solution | Subcutaneous injection | N.A. | N.A. |
| 1535 | Th1114 | Preotact | Parathyroid hormone: Full view | 84 | Ib | Osteological | Preotact | Nycomed | N.A. | Subcutaneous injection | N.A. | Parathyroid hormone/parathyroid hormone-related peptide receptor,Parathyroid hormone 2 receptor |
| 1537 | Th1116 | Canakinumab | H-GAMMA-1 (VH(1-118) Full view | 842 | IIIb | Immunological | ILARIS | Novartis Pharmaceuticals | White, preservative-free, lyophilized powder | Subcutaneous injection | Anti-Inflammatory Agents and Monoclonal antibodies | Interleukin-1 beta |
| 1550 | Th1119 | Tocilizumab | N.A. Full view | 0 | IIa | Immunological | ACTEMRA | Genentech | Sterile, preservative-free solution, colorless to pale yellow liquid, with a pH of about 6.5 | Intravenous infusion, Subcutaneous injection | N.A. | Interleukin-6 receptor subunit alpha |
| 1556 | Th1120 | Teriparatide | Parathyroid hormone Full view | 34 | Ib | Osteological | Forteo | Eli Lilly and Company | Sterile, colorless, clear, isotonic solution | Subcutaneous injection | Bone Density Conservation Agents | Parathyroid hormone/parathyroid hormone-related peptide receptor |
| 1562 | Th1122 | Rilonacept | rilonacept|Homo sapi Full view | 880 | IIa | Immunological | Arcalyst | Regeneron Pharmaceuticals | Sterile, white to off-white, lyophilized powder | Subcutaneous injection | Immunosuppressive Agents | Interleukin-1 beta,Interleukin-1 alpha,Interleukin-1 receptor antagonist protein |
| 1576 | Th1124 | Liraglutide | HAEGTFTSDVSSYLEGQAAK Full view | 33 | Ib | Hormonal | Saxenda | Novo Nordisk | Clear, colorless solution | Subcutaneous injection | N.A. | Glucagon-like peptide 1 receptor |
| 1577 | Th1124 | Liraglutide | HAEGTFTSDVSSYLEGQAAK Full view | 33 | Ib | Hormonal | Victoza | Novo Nordisk | Clear, colorless solution. | Subcutaneous injection | N.A. | Glucagon-like peptide 1 receptor |
| 1583 | Th1125 | Golimumab | N.A. Full view | 0 | IIb | Immunological | Simponi Injection | N.A. | Clear to slightly opalescent, colorless to light yellow solution | Subcutaneous injection | Antipsoriatic Agents and Monoclonal antibodies and TNF inhibitor | Tumor necrosis factor |
| 1601 | Th1127 | Buserelin | pGlu-His-Trp-Ser-Tyr Full view | 9 | IIIc | Cancer/Hormonal | Suprecur (injection) | Sanofi-Aventis | 1mg/ml Injection | Subcutaneous injection | N.A. | Lutropin-choriogonadotropic hormone receptor,Gonadotropin-releasing hormone receptor |
| 1603 | Th1129 | Tesamorelin | YADAIFTNSYRKVLGQLSAR Full view | 44 | Ib | Hormonal | Egrifta | Theratechnologies | Sterile, white to off-white, preservative-free lyophilized powder | Subcutaneous injection | N.A. | Growth hormone-releasing hormone receptor |
| 1624 | Th1137 | Teduglutide | HGDGSFSDEMNTILDNLAAR Full view | 33 | Ia | Malabsorption disorder | Gattex | NPS Pharmaceuticals, Inc | Clear, colorless to light-straw–colored liquid. | Subcutaneous injection | N.A. | Glucagon-like peptide 2 receptor |
| 1628 | Th1139 | Certolizumab Pegol | Light chain: DIQMTQS Full view | 443 | IIb | Immunologcal | Cimzia | UCB | Sterile, white, lyophilized powder for solution or as a sterile, solution in a single-use prefilled 1 mL glass syringe | Subcutaneous injection | TNF inhibitor | Tumor necrosis factor |
| 1634 | Th1140 | Insulin, Isophane Or Nph Insulin (Neutral Protamine Hagedorn) | A chain: GIVEQCCTSIC Full view | 51 | Ia | Hormonal/Metabolic | Novolin N | Novo Nordisk | Novolin N InnoLet (nph, human insulin isophane suspension 3 ml disposable prefilled syringe) | Subcutaneous injection | Hypoglycemic Agents and Antidiabetic Agents | Insulin receptor |
| 1638 | Th1144 | Follitropin Alpha | N.A. Full view | 0 | Ib | Adjunct therapy/ Hormonal | Gonal-F | Serono Laboratories | Sterile, lyophilized powder. | Subcutaneous injection | N.A. | N.A. |
| 1639 | Th1144 | Follitropin Alpha | N.A. Full view | 0 | Ib | Adjunct therapy/ Hormonal | Gonal-f RFF | EMD SERONO | Sterile, lyophilized powde | Subcutaneous injection | N.A. | N.A. |
| 1640 | Th1145 | Romiplostim | Thrombopoietin recep Full view | 269 | Ib | Immunologcal | Nplate | Amgen | Sterile, preservative-free, lyophilized, solid white powder | Subcutaneous injection | Colony-Stimulating Factors and Thrombopoietic Agents | N.A. |
| 1654 | Th1150 | Secukinumab | Secukinumab Heavy Ch Full view | 672 | IIa | Immunological | Cosentyx | Novartis Pharmaceuticals Corporation | Sterile, preservative-free, clear to slightly opalescent, colorless to slightly yellow solution. | Subcutaneous injection | Inhibitor | IL-17A cytokine |
| 1655 | Th1151 | Somatotropin Recombinant | FPTIPLSRLFDNAMLRAHRL Full view | 192 | Ib | Hormonal/Metabolic | NutropinAQ | Genentech Inc. | Sterile, white lyophilized powder intended for subcutaneous administration after reconstitution with Bacteriostatic Water | Subcutaneous administration | Hormone Replacement Agents | Growth hormone receptor, Prolactin receptor |
| 1656 | Th1151 | Somatotropin Recombinant | FPTIPLSRLFDNAMLRAHRL Full view | 192 | Ib | Hormonal/Metabolic | BioTropin | Bio-Technology General (Israel) Ltd. | Sterile, white, lyophilized powder | Subcutaneous administration | Hormone Replacement Agents | Growth hormone receptor, Prolactin receptor |
| 1657 | Th1151 | Somatotropin Recombinant | FPTIPLSRLFDNAMLRAHRL Full view | 192 | Ib | Hormonal/Metabolic | Protropin | Genentech Inc. | Sterile, white, lyophilized powder | Intramuscular or subcutaneous administration | Hormone Replacement Agents | Growth hormone receptor, Prolactin receptor |
| 1666 | Th1157 | Sermorelin | YADAIFTNSYRKVLGQLSAR Full view | 30 | Ia | Hormonal | Sermorelin acetate | Emd serono inc | Sterile, non-pyrogenic, lyophilized powder | Subcutaneous Injection | Hormone Replacement Agents | Growth hormone-releasing hormone receptor |
| 1674 | Th1161 | Albiglutide | HGEGTFTSDVSSYLEGQAAK Full view | 645 | Ib | Hormonal disorders | Eperzan | Glaxosmithkline Inc | Powder for Solution | Subcutaneous | Drugs used in diabetes; alimentary tract and metabolism; blood glucose lowering drugs, excl. insulins. | Glucagon-like peptide 1 receptor |
| 1676 | Th1161 | Albiglutide | HGEGTFTSDVSSYLEGQAAK Full view | 645 | Ib | Hormonal disorders | Tanzeum | Glaxo Smith Kline Llc | Injection, Powder, Lyophilized, for Solution | Subcutaneous | Drugs used in diabetes; alimentary tract and metabolism; blood glucose lowering drugs, excl. insulins. | Glucagon-like peptide 1 receptor |
| 1678 | Th1162 | Alirocumab | NA Full view | 0 | Ic | Metabolic/Cardiac | Praluent | Sanofi Aventis U.S. Llc | Injection, Solution | Subcutaneous | N.A. | Proprotein convertase subtilisin/kexin type 9 |
| 1679 | Th1162 | Alirocumab | NA Full view | 0 | Ic | Metabolic/Cardiac | Praluent | Sanofi Aventis Canada Inc | Solution | Subcutaneous | N.A. | Proprotein convertase subtilisin/kexin type 10 |
| 1680 | Th1162 | Alirocumab | NA Full view | 0 | Ic | Metabolic/Cardiac | Praluent | Sanofi Aventis Canada Inc | Solution | Subcutaneous | N.A. | Proprotein convertase subtilisin/kexin type 11 |
| 1681 | Th1162 | Alirocumab | NA Full view | 0 | Ic | Metabolic/Cardiac | Praluent | Sanofi Aventis U.S. Llc | Injection, Solution | Subcutaneous | N.A. | Proprotein convertase subtilisin/kexin type 14 |
| 1682 | Th1163 | Ancestim | NA Full view | 0 | Ib | Cancer | Stemgen | Biovitrum Ab (publ) | NA | Subcutaneous | NA | NA |
| 1694 | Th1166 | Asfotase Alfa | LVPEKEKDPKYWRDQAQETL Full view | 726 | Ia | Genetic Disorders | Strensiq | Alexion Pharma Ghbh | Solution | Subcutaneous | Enzymes Alimentary Tract and Metabolism | Sphingosine 1-phosphate receptor 1; Pyrophosphate |
| 1695 | Th1166 | Asfotase Alfa | LVPEKEKDPKYWRDQAQETL Full view | 726 | Ia | Genetic Disorders | Strensiq | Alexion Pharmaceuticals Inc. | Solution | Subcutaneous | Enzymes Alimentary Tract and Metabolism | Sphingosine 1-phosphate receptor 1; Pyrophosphate |
| 1726 | Th1175 | Desirudin | NA Full view | 0 | Ib | Hematological Disorders | Iprivask | Valeant Pharmaceuticals North America LLC | NA | Subcutaneous | NA | NA |
| 1729 | Th1176 | Dulaglutide | HGEGTFTSDVSSYLEEQAAK Full view | 275 | Ib | Metabolic Disorders | Trulicity | Eli Lilly and Company | Solution, Injection | Subcutaneous | Hypoglycemic Agents; Drugs Used in Diabetes; Alimentary Tract and Metabolism; Blood Glucose Lowering Drugs, Excl. Insulins | Glucagon-like peptide 1 receptor |
| 1730 | Th1176 | Dulaglutide | HGEGTFTSDVSSYLEEQAAK Full view | 275 | Ib | Metabolic Disorders | Trulicity | Eli Lilly Canada Inc | Solution | Subcutaneous | Hypoglycemic Agents; Drugs Used in Diabetes; Alimentary Tract and Metabolism; Blood Glucose Lowering Drugs, Excl. Insulins | Glucagon-like peptide 1 receptor |
| 1741 | Th1179 | Evolocumab | NA Full view | 0 | IIa | Genetic/Metabolic/Cardiac | NA | NA | Injection, Solution; Injection | Subcutaneous | Lipid Modifying Agents, Plain; Cardiovascular System | Proprotein convertase subtilisin/kexin type 9 |
| 1742 | Th1179 | Evolocumab | NA Full view | 0 | IIa | Genetic/Metabolic/Cardiac | Repatha | Amgen Inc | Injection, Solution | Subcutaneous | Lipid Modifying Agents, Plain; Cardiovascular System | Proprotein convertase subtilisin/kexin type 10 |
| 1743 | Th1179 | Evolocumab | NA Full view | 0 | IIa | Genetic/Metabolic/Cardiac | Repatha | Amgen Canada Inc | Solution | Subcutaneous | Lipid Modifying Agents, Plain; Cardiovascular System | Proprotein convertase subtilisin/kexin type 11 |
| 1744 | Th1179 | Evolocumab | NA Full view | 0 | IIa | Genetic/Metabolic/Cardiac | Repatha | Amgen Inc | Injection, Solution | Subcutaneous | Lipid Modifying Agents, Plain; Cardiovascular System | Proprotein convertase subtilisin/kexin type 12 |